Aberrant expression of the negative costimulator PD-1 on T cells in granulomatosis with polyangiitis

Rheumatology (United Kingdom)

Volumn 51, Issue 7, 2012, Pages 1188-1197

  Wilde, Benjamin ^a,b   Hua, Fan ^a,c   Dolff, Sebastian ^a   Jun, Cao ^a,d   Cai, Xin ^a   Specker, Christof ^e   Feldkamp, Thorsten ^a   Kribben, Andreas ^a   Cohen Tervaert, Jan Willem ^b   Witzke, Oliver ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d CHONGQING MEDICAL UNIVERSITY   (China)

^e Eye Hospital   (Germany)

Author keywords

ANCA; PD 1; T cells; Vasculitis

Indexed keywords

PROGRAMMED DEATH 1 RECEPTOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HELPER CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; WEGENER GRANULOMATOSIS;

BIOPSY; CELL PROLIFERATION; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNITY, CELLULAR; IMMUNOHISTOCHEMISTRY; INTRACELLULAR FLUID; KIDNEY; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; PROGRAMMED CELL DEATH 1 RECEPTOR; T-LYMPHOCYTES; WEGENER GRANULOMATOSIS;

EID: 84863840695     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kes034     Document Type: Article

References (50)

1. Falk RJ, Gross WL, Guillevin L et al. Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. Arthritis Rheum 2011;63: 863-4.
2. Tervaert JW, van der Woude FJ, Fauci AS et al. Association between active Wegener's granulomatosis and anticytoplasmic antibodies. Arch Intern Med 1989; 149:2461-5.
3. Leavitt RY, Fauci AS, Bloch DA et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 1990; 33:1101-7.
4. Jennette JC, Falk RJ, Andrassy K et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994;37:187-92.
5. Wilde B, Van Paassen P, Witzke O, Cohen Tervaert JW. New pathophysiological insights and treatment of ANCA-associated vasculitis. Kidney Int 2011;79:599-612.
6. Wilde B, Thewissen M, Damoiseaux J et al. T-cells in ANCA-associated vasculitis: what can we learn from lesional versus circulating T-cells? Arthritis Res Ther 2010; 12:204.
7. Gephardt GN, Ahmad M, Tubbs RR. Pulmonary vasculitis (Wegener's granulomatosis). Immunohistochemical study of T and B cell markers. Am J Med 1983;74:700-4.
8. Bolton WK, Innes DJ Jr, Sturgill BC, Kaiser DL. T-cells and macrophages in rapidly progressive glomerulonephritis: clinicopathologic correlations. Kidney Int 1987;32:869-76.
9. Saunders BM, Frank AA, Orme IM, Cooper AM. CD4 is required for the development of a protective granulomatous response to pulmonary tuberculosis. Cell Immunol 2002;216:65-72.
10. Co DO, Hogan LH, Il-Kim S, Sandor M. T cell contributions to the different phases of granuloma formation. Immunol Lett 2004;92:135-42.
11. Brouwer E, Tervaert JW, Horst G et al. Predominance of IgG1 and IgG4 subclasses of anti-neutrophil cytoplasmic autoantibodies (ANCA) in patients with Wegener's granulomatosis and clinically related disorders. Clin Exp Immunol 1991;83:379-86.
12. Stegeman CA, Tervaert JW, Huitema MG, Kallenberg CG. Serum markers of T cell activation in relapses of Wegener's granulomatosis. Clin Exp Immunol 1993;91: 415-20.
13. Popa ER, Stegeman CA, Bos NA, Kallenberg CGM, Tervaert JWC. Differential B- and T-cell activation in Wegener's granulomatosis. J Allergy Clin Immunol 1999; 103:885-94.
14. Abdulahad WH, van der Geld YM, Stegeman CA, Kallenberg CG. Persistent expansion of CD4+ effector memory T cells in Wegener's granulomatosis. Kidney Int 2006;70:938-47.
15. Wilde B, Dolff S, Cai X et al. CD4+CD25+ T-cell populations expressing CD134 and GITR are associated with disease activity in patients with Wegener's granulomatosis. Nephrol Dial Transplant 2009;24:161-71.
16. Brusko TM, Putnam AL, Bluestone JA. Human regulatory T cells: role in autoimmune disease and therapeutic opportunities. Immunol Rev 2008;223:371-90.
17. Fife BT, Bluestone JA. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev 2008;224:166-82.
18. Ansari MJ, Salama AD, Chitnis T et al. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med 2003;198: 63-9.
19. Salama AD, Chitnis T, Imitola J et al. Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. J Exp Med 2003;198:71-8.
20. Tanaka K, Albin MJ, Yuan X et al. PDL1 is required for peripheral transplantation tolerance and protection from chronic allograft rejection. J Immunol 2007;179:5204-10.
21. Wolchok JD, Yang AS, Weber JS. Immune regulatory antibodies: are they the next advance? Cancer J 2010;16: 311-7.
22. Wan B, Nie H, Liu A et al. Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis. J Immunol 2006;177:8844-50.
23. Bertsias GK, Nakou M, Choulaki C et al. Genetic, immunologic, and immunohistochemical analysis of the programmed death 1/programmed death ligand 1 pathway in human systemic lupus erythematosus. Arthritis Rheum 2009;60:207-18.
24. Trabattoni D, Saresella M, Pacei M et al. Costimulatory pathways in multiple sclerosis: distinctive expression of PD-1 and Pd-L1 in patients with different patterns of disease. J Immunol 2009;183:4984-93.
25. Kristjansdottir H, Steinsson K, Gunnarsson I et al. Lower expression levels of the programmed death 1 receptor on CD4+CD25+ T cells and correlation with the PD-1.3A genotype in patients with systemic lupus erythematosus. Arthritis Rheum 2010;62:1702-11.
26. Raptopoulou AP, Bertsias G, Makrygiannakis D et al. The programmed death 1/programmed death ligand 1 inhibitory pathway is up-regulated in rheumatoid synovium and regulates peripheral T cell responses in human and murine arthritis. Arthritis Rheum 2010;62:1870-80.
27. Slot MC, Sokolowska MG, Savelkouls KG et al. Immunoregulatory gene polymorphisms are associated with ANCA-related vasculitis. Clin Immunol 2008;128: 39-45.
28. Hellmich B, Flossmann O, Gross WL et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 2007;66:605-17.
29. Venken K, Hellings N, Broekmans T et al. Natural naive CD4+CD25+CD127low regulatory T cell (Treg) development and function are disturbed in multiple sclerosis patients: recovery of memory Treg homeostasis during disease progression. J Immunol 2008;180:6411-20.
30. Berden AE, Ferrario F, Hagen EC et al. Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol 2010;21:1628-36.
31. Iwai Y, Okazaki T, Nishimura H et al. Microanatomical localization of PD-1 in human tonsils. Immunol Lett 2002;83: 215-20.
32. Wilde B, van Paassen P, Damoiseaux J et al. Dendritic cells in renal biopsies of patients with ANCA-associated vasculitis. Nephrol Dial Transplant 2009;24:2151-6.
33. Marinaki S, Kalsch AI, Grimminger P et al. Persistent T-cell activation and clinical correlations in patients with ANCA-associated systemic vasculitis. Nephrol Dial Transplant 2006;21:1825-32.
34. Marinaki S, Neumann I, Kalsch AI et al. Abnormalities of CD4 T cell subpopulations in ANCA-associated vasculitis. Clin Exp Immunol 2005;140:181-91.
35. Morgan MD, Pachnio A, Begum J et al. CD4+CD28- T cell expansion in granulomatosis with polyangiitis (Wegener's) is driven by latent cytomegalovirus infection and is associated with an increased risk of infection and mortality. Arthritis Rheum 2011;63:2127-37.
36. Nishimura H, Honjo T. PD-1: an inhibitory immunoreceptor involved in peripheral tolerance. Trends Immunol 2001;22: 265-8.
37. Freeman GJ, Long AJ, Iwai Y. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000;192:1027-34.
38. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 2010;236: 219-42.
39. Steiner K, Moosig F, Csernok E et al. Increased expression of CTLA-4 (CD152) by T and B lymphocytes in Wegener's granulomatosis. Clin Exp Immunol 2001;126:143-50.
40. Carter LL, Fouser LA, Jussif J et al. PD-1:PD-L inhibitory pathway affects both CD4+ and CD8+ T cells and is overcome by IL-2. Eur J Immunol 2002;32:634-43.
41. Bennett F, Luxenberg D, Ling V et al. Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses. J Immunol 2003;170:711-8.
42. Prokunina L, Castillejo-Lopez C, Oberg F et al. A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet 2002;32:666-9.
43. Kroner A, Mehling M, Hemmer B et al. A PD-1 polymorphism is associated with disease progression in multiple sclerosis. Ann Neurol 2005;58:50-7.
44. Fife BT, Pauken KE, Eagar TN et al. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol 2009;10:1185-92.
45. Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol 2007; 8:239-45.
46. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol 2004;23:515-48.
47. Kasagi S, Kawano S, Okazaki T et al. Anti-programmed cell death 1 antibody reduces CD4+PD-1+ T cells and relieves the lupus-like nephritis of NZB/W F1 mice. J Immunol 2006;184:2337-47.
48. Kobayashi M, Kawano S, Hatachi S et al. Enhanced expression of programmed death-1 (PD-1)/PD-L1 in salivary glands of patients with Sjögren's syndrome. J Rheumatol 2005;32:2156-63.
49. Starke A, Lindenmeyer MT, Segerer S et al. Renal tubular PD-L1 (CD274) suppresses alloreactive human T-cell responses. Kidney Int 2010;78:38-47.
50. Abdulahad WH, Kallenberg CG, Limburg PC, Stegeman CA. Urinary CD4+ effector memory T cells reflect renal disease activity in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2009;60: 2830-8.